Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 3;11:573156. doi: 10.3389/fimmu.2020.573156

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Fazzi, Petrini, Giuliani, Morganti, Carulli, Dalla Palma, Notarfranchi, Galimberti and Buda

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

(A) Average with standard deviation of the number of effector (CD45RO−CD27−) γδ lymphocytes before the beginning and after 8 days of treatment at cycles: 1, 3, and 6. (B) Average with standard deviation of the number of late effector (CD45RO+CD27−) γδ lymphocytes before the beginning and after 8 days of treatment at cycles: 1, 3, and 6. (C) Average with standard deviation of the number of memory (CD45RO−CD27+) γδ lymphocytes before the beginning and after 8 days of treatment at cycles: 1, 3, and 6. (D) Time to progression of patients with a high and low (dotted line) number of memory γδ lymphocytes (according to their median number) in bone marrow before the beginning of the maintenance treatment. (E) Average with standard deviation of the number of naïve (CD45RO−CD27−) γδ lymphocytes before the beginning and after 8 days of treatment at cycles: 1, 3, and 6. (F) Average with standard deviation of the number of Vγ9δ2 lymphocytes before the beginning and after 8 days of treatment at cycles: 1, 3, and 6. Stars indicate statistically significant differences.